secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2021-10-26T23:59:59+00:00
Accession:  0001193125-21-307134
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio expands board to 15, appoints Dr. Hannah Valantine as director effective Oct 23, 2021
--------------------------------------------------------------------------------

- Board of Directors expanded from 14 to 15 members; Dr. Hannah Valantine appointed as Class I director effective Oct 23, 2021.
- Dr. Valantine received option to purchase $1,200,000 of common stock at $48.45 per share, vesting over three years.
- She currently serves as Professor of Medicine at Stanford and was former Chief Officer for Scientific Workforce Diversity at NIH (2014-2020).
- Dr. Valantine co-invented organ donor-derived cell-free DNA technology for transplant rejection monitoring.
- She also serves on boards of Pacific Biosciences (PACB) and CareDx (CDNA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/0001193125-21-307134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312521307134/d164687d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-307134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer